<?xml version="1.0" encoding="UTF-8"?>
<p id="par0080">In January 2017, and again in February 2018, the WHO included Nipah and related henipaviral diseases on its list of priority diseases for investment in research and development for diagnostics, prevention, and treatments (
 <xref rid="bib0185" ref-type="bibr">WHO, 2018a</xref>). In a related announcement in January 2017, Nipah virus was listed as one of three viruses (along with Lassa virus and Middle East respiratory syndrome coronavirus (MERS-CoV)) that would be prioritized by the new Coalition for Epidemic Preparedness Innovations (CEPI) for vaccine development (
 <xref rid="bib0145" ref-type="bibr">Rottingen et al., 2017</xref>). Currently there are no US Food and Drug Administration (FDA)-licensed Nipah vaccines, antiviral drugs, or immunotherapies for humans, although candidates exist in the early stages of development (
 <xref rid="bib0020" ref-type="bibr">Broder et al., 2016</xref>, 
 <xref rid="bib0150" ref-type="bibr">Satterfield et al., 2016</xref>).
</p>
